Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 73

Sort by

Sort Order Select

Journal Articles

Safety and Efficacy of G-CSF with Intensive Chemotherapy in Newly Diagnosed Acute Myeloid Leukemia: A Subgroup Analysis of the Phase II Trial of Venetoclax in Combination with Cladribine, Idarubicin, and Cytarabine

Blood (2024) 144 (Supplement 1): 446.

https://doi.org/10.1182/blood-2024-203938

Published: 2024

Journal Articles

Phase 1b/2 Study of Magrolimab (Magro), Azacitidine (AZA) and Venetoclax (VEN) in Patients (pts) with Newly Diagnosed (ND) Older/Unfit or High Risk Acute Myeloid Leukemia (AML) and Relapsed Refractory (R/R) AML: Final Clinical Data and Genomic Markers of Resistance/Relapse

Blood (2024) 144 (Supplement 1): 735.

https://doi.org/10.1182/blood-2024-203706

Published: 2024

Journal Articles

A Phase II Trial of Venetoclax in Combination with Cladribine, Idarubicin, and Cytarabine in Newly Diagnosed Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome

Blood (2024) 144 (Supplement 1): 734.

https://doi.org/10.1182/blood-2024-203459

Published: 2024

Journal Articles

Incidence, Characteristics, and Outcomes of Patients with Newly Diagnosed, De Novo KIT -Mutated Non-Core Binding Factor Acute Myeloid Leukemia without Systemic Mastocytosis

Eitan Kugler, Sanam Loghavi, Farhad Ravandi, Courtney D. DiNardo, Naval Daver, Tapan M. Kadia, Gautam Borthakur, Ghayas C. Issa, Hussein A. Abbas, Prithviraj Bose, Jayastu Senapati, Hagop M. Kantarjian, Nicholas J. Short

Blood (2024) 144 (Supplement 1): 2857.

https://doi.org/10.1182/blood-2024-199917

Published: 2024

Journal Articles

Older Age and TP53 Mutations Are Predictors for the Development of Therapy-Related Myeloid Neoplasms in Adults Undergoing Frontline Therapy for Acute Lymphoblastic Leukemia

Roberta Santos Azevedo, Hagop M. Kantarjian, Koichi Takahashi, Cedric Christophe Nasnas, Sanam Loghavi, Nitin Jain, Fadi G. Haddad, Jayastu Senapati, Ghayas C. Issa, Hussein A. Abbas, Tapan M. Kadia, Kelly S. Chien, Guillermo Montalban-Bravo, Rebecca Garris, Farhad Ravandi, Elias Jabbour, Nicholas J. Short

Blood (2024) 144 (Supplement 1): 728.

https://doi.org/10.1182/blood-2024-207745

Published: 2024

Journal Articles

Treatment Intensity in Acute Myeloid Leukemia with Extramedullary Disease

Blood (2024) 144 (Supplement 1): 2851.

https://doi.org/10.1182/blood-2024-202429

Published: 2024

Journal Articles

Blood-Based Proteomic Profiling Identifies Osmr As a Novel Biomarker

Hussein A. Abbas, Bofei Wang, Jennifer Marvin-Peek, Bin Yuan, Araceli Isabella Garza, Jessica Lynn Root, Andrea Arruda, Yiwei Liu, Courtney D. DiNardo, Tapan M. Kadia, Naval Daver, Philip L Lorenzi, Koji Sasaki, Steven M. Kornblau, Mark D. Minden, Farhad Ravandi, Hagop M. Kantarjian, Patrick K. Reville

Blood (2024) 144 (Supplement 1): 2912.

https://doi.org/10.1182/blood-2024-201725

Published: 2024

Journal Articles

Multi-Omic Analyses of TP53 -Mutated Acute Myeloid Leukemia Identify Prognostic Metabolic Signatures

Jayakumar Vadakekolathu, Sarah Skuli, David J Boocock, Clare Coveney, Eruchi G Ikpo, Bofei Wang, Elena M Fenu, Hussein A. Abbas, Catherine E. Lai, Martin P Carroll, Sergio Rutella

Blood (2024) 144 (Supplement 1): 2911.

https://doi.org/10.1182/blood-2024-201311

Published: 2024

Journal Articles

Efficacy of a Novel BCL-XL Degrader, DT2216, in Preclinical Models of Post-Myeloproliferative Neoplasm Secondary AML

Blood (2024) 144 (Supplement 1): 2749.

https://doi.org/10.1182/blood-2024-194031

Published: 2024

Journal Articles

Less May be More: The Impact of Post-Remission Intensive (IC) Consolidation Cycles on Outcomes in Newly Diagnosed Acute Myeloid Leukemia Receiving IC + Venetoclax

Jennifer Marvin-Peek, Courtney D. DiNardo, Wei-Ying Jen, Nicholas J. Short, Yesid Alvarado Valero, Gautam Borthakur, Naval Daver, Eitan Kugler, Alexandre Bazinet, Hussein A. Abbas, Musa Yilmaz, Guillermo Garcia-Manero, Hagop M. Kantarjian, Tapan M. Kadia

Blood (2024) 144 (Supplement 1): 1472.

https://doi.org/10.1182/blood-2024-202405

Published: 2024

Journal Articles

Multimodal Spatial Transcriptomic Profiling Elucidates Niche-Specific Dynamics in Medullary and Extramedullary Acute Myeloid Leukemia

Enes Dasdemir, Ivo Veletic, Christopher P. Ly, Andres E Quesada, Fatima Z Jelloul, Pamella Borges, Sreyashi Basu, Sonali Jindal, Zhiqiang Wang, Alexander J Lazar, Khalida M Wani, Dinler A Antunes, Patrick K. Reville, Preethi Gunaratne, Robert J Tower, Padmanee Sharma, Hussein A. Abbas

Blood (2024) 144 (Supplement 1): 1059.

https://doi.org/10.1182/blood-2024-201932

Published: 2024

Journal Articles

Enhancing Macrophage Mediated Phagocytosis in AML: The Complementary Mechanisms of Venetoclax and Azacitidine Combination Therapy

Zhe WANG, Xufeng Chen, Simone Sidoli, Anna Skwarska, Yannan Jia, Lei Yang, Varun Gupta, Shikhar Sharma, Iannis Aifantis, Hussein A. Abbas, Naval Daver, Qi Zhang Tatarata, Marina Konopleva

Blood (2024) 144 (Supplement 1): 207.

https://doi.org/10.1182/blood-2024-198057

Published: 2024

Journal Articles

Long-Term Survival Outcomes and Cytogenetic/Molecular Patterns of Relapse in Adults with FLT3 -Mutated AML Receiving Frontline Triplet Therapy with a Hypomethylating Agent, Venetoclax and FLT3 Inhibitor

Nicholas J. Short, Sanam Loghavi, Musa Yilmaz, Omer Karrar, Joseph E. Jabbour, Courtney D. DiNardo, Tapan M. Kadia, Gautam Borthakur, Ghayas C. Issa, Hussein A. Abbas, Marina Konopleva, Farhad Ravandi, Hagop M. Kantarjian, Naval Daver

Blood (2024) 144 (Supplement 1): 220.

https://doi.org/10.1182/blood-2024-210891

Published: 2024

Journal Articles

Phase I/II Study of the All-Oral Combination of Revumenib (SNDX-5613) with Decitabine/Cedazuridine (ASTX727) and Venetoclax (SAVE) in R/R AML

Blood (2024) 144 (Supplement 1): 216.

https://doi.org/10.1182/blood-2024-204375

Published: 2024

Journal Articles

A Retrospective Analysis of Ponatinib-Based Therapy in Patients with Myeloid Blast Phase Chronic Myeloid Leukemia: Responses Rates, Outcomes and Patterns of Relapse

Omer Karrar, Elias Jabbour, Jayastu Senapati, Fadi G. Haddad, Ghayas C. Issa, Koji Sasaki, Hussein A. Abbas, Sara Emogene Dellasala, Farhad Ravandi, Hagop M. Kantarjian, Nicholas J. Short

Blood (2024) 144 (Supplement 1): 3156.

https://doi.org/10.1182/blood-2024-206644

Published: 2024

Journal Articles

Comparison of Anti-PD1, Anti-CTLA4 and Anti-TIM3 in Treatment of AML Patients with Single-Cell Transcriptomics Displays Different Effects on Immune Subtypes

Sofia Forstén, Livius Penter, Oscar E. Brück, Johannes Smolander, Karita Peltonen, Harri Lähdesmäki, Mika Kontro, Kimmo Porkka, Hussein A. Abbas, Catherine J. Wu, Jani Huuhtanen, Satu Mustjoki

Blood (2024) 144 (Supplement 1): 1529.

https://doi.org/10.1182/blood-2024-199471

Published: 2024

Journal Articles

ICASA: An Interactive Comprehensive Atlas of Single Cells in AML from 82 Bone Marrow Samples

Bofei Wang, Poonam N Desai, Jae Jun Ku, Naval Daver, Patrick K. Reville, Hussein A. Abbas

Blood (2024) 144 (Supplement 1): 2213.

https://doi.org/10.1182/blood-2024-202595

Published: 2024

Journal Articles

Safety and Efficacy of a Novel Mammalian-Derived Asparaginase without Glutaminase Activity in Combination with Venetoclax for Acute Myeloid Leukemia

Dhabya Majid, Zhe WANG, Bin Yuan, Mhd Yousuf Yassouf, Amanda Schalk, Basant T. Gamal, Qi Zhang Tatarata, Jessica Lynn Root, Araceli Isabella Garza, Annie Hoai Nguyen, Sammy Ferri-Borgogno, Patrick K. Reville, Arnon Lavie, Hussein A. Abbas

Blood (2024) 144 (Supplement 1): 2777.

https://doi.org/10.1182/blood-2024-203584

Published: 2024

Journal Articles

Multimodal Spatial Profiling in Acute Myeloid Leukemia

Christopher P. Ly, Ivo Veletic, Christopher D. Pacheco, Enes Dasdemir, Fatima Z Jelloul, Sammy Ferri-Borgogno, Akshay Basi, Javier A. Gomez, Jessica Lynn Root, Patrick K. Reville, Andres E Quesada, Carlos E. Bueso-Ramos, Miriam B. Garcia, Jared K. Burks, Hussein A. Abbas

Blood (2024) 144 (Supplement 1): 2681.

https://doi.org/10.1182/blood-2024-203816

Published: 2024

Journal Articles

Temporal Dynamics of Bone Marrow Fibrocytes in the Progression of Primary Myelofibrosis

Ivo Veletic, Taghi Manshouri, C. Cameron Yin, Christopher D. Pacheco, Christopher P. Ly, Enes Dasdemir, Evan N. Cohen, Lucia Masarova, Naveen Pemmaraju, Prithviraj Bose, Hagop M. Kantarjian, Zeev Estrov, Patrick K. Reville, Andrew Dunbar, Hussein A. Abbas

Blood (2024) 144 (Supplement 1): 1760.

https://doi.org/10.1182/blood-2024-211966

Published: 2024

NARROW

Safety and Efficacy of G-CSF with Intensive Chemotherapy in Newly Diagnosed Acute Myeloid Leukemia: A Subgroup Analysis of the Phase II Trial of Venetoclax in Combination with Cladribine, Idarubicin, and Cytarabine

Phase 1b/2 Study of Magrolimab (Magro), Azacitidine (AZA) and Venetoclax (VEN) in Patients (pts) with Newly Diagnosed (ND) Older/Unfit or High Risk Acute Myeloid Leukemia (AML) and Relapsed Refractory (R/R) AML: Final Clinical Data and Genomic Markers of Resistance/Relapse

A Phase II Trial of Venetoclax in Combination with Cladribine, Idarubicin, and Cytarabine in Newly Diagnosed Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome

Incidence, Characteristics, and Outcomes of Patients with Newly Diagnosed, De Novo KIT -Mutated Non-Core Binding Factor Acute Myeloid Leukemia without Systemic Mastocytosis

Older Age and TP53 Mutations Are Predictors for the Development of Therapy-Related Myeloid Neoplasms in Adults Undergoing Frontline Therapy for Acute Lymphoblastic Leukemia

Treatment Intensity in Acute Myeloid Leukemia with Extramedullary Disease

Blood-Based Proteomic Profiling Identifies Osmr As a Novel Biomarker

Multi-Omic Analyses of TP53 -Mutated Acute Myeloid Leukemia Identify Prognostic Metabolic Signatures

Efficacy of a Novel BCL-XL Degrader, DT2216, in Preclinical Models of Post-Myeloproliferative Neoplasm Secondary AML

Less May be More: The Impact of Post-Remission Intensive (IC) Consolidation Cycles on Outcomes in Newly Diagnosed Acute Myeloid Leukemia Receiving IC + Venetoclax

Multimodal Spatial Transcriptomic Profiling Elucidates Niche-Specific Dynamics in Medullary and Extramedullary Acute Myeloid Leukemia

Enhancing Macrophage Mediated Phagocytosis in AML: The Complementary Mechanisms of Venetoclax and Azacitidine Combination Therapy

Long-Term Survival Outcomes and Cytogenetic/Molecular Patterns of Relapse in Adults with FLT3 -Mutated AML Receiving Frontline Triplet Therapy with a Hypomethylating Agent, Venetoclax and FLT3 Inhibitor

Phase I/II Study of the All-Oral Combination of Revumenib (SNDX-5613) with Decitabine/Cedazuridine (ASTX727) and Venetoclax (SAVE) in R/R AML

A Retrospective Analysis of Ponatinib-Based Therapy in Patients with Myeloid Blast Phase Chronic Myeloid Leukemia: Responses Rates, Outcomes and Patterns of Relapse

Comparison of Anti-PD1, Anti-CTLA4 and Anti-TIM3 in Treatment of AML Patients with Single-Cell Transcriptomics Displays Different Effects on Immune Subtypes

ICASA: An Interactive Comprehensive Atlas of Single Cells in AML from 82 Bone Marrow Samples

Safety and Efficacy of a Novel Mammalian-Derived Asparaginase without Glutaminase Activity in Combination with Venetoclax for Acute Myeloid Leukemia

Multimodal Spatial Profiling in Acute Myeloid Leukemia

Temporal Dynamics of Bone Marrow Fibrocytes in the Progression of Primary Myelofibrosis

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only